Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: a prospective, open-label, randomized, controlled study in Korean patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples